PMID- 32276006
OWN - NLM
STAT- MEDLINE
DCOM- 20210617
LR  - 20210617
IS  - 1873-4995 (Electronic)
IS  - 0168-3659 (Linking)
VI  - 322
DP  - 2020 Jun 10
TI  - Stimuli-responsive nano-assemblies for remotely controlled drug delivery.
PG  - 566-592
LID - S0168-3659(20)30209-1 [pii]
LID - 10.1016/j.jconrel.2020.03.051 [doi]
AB  - Stimuli-responsive nano-assemblies are emerging as promising drug delivery 
      systems (DDSs) with spatial and temporal tenability, which can undergo structural 
      transition for controlled drug release upon excitation by either exogenous or 
      endogenous stimuli. Particularly, exogenous stimuli-responsive nano-assemblies 
      based remotely controlled DDSs, have received much attention due to their 
      accuracy and reliability realized by tunable exogenous triggers such as light, 
      magnetic field, or temperature. In this review, we will briefly introduce the 
      current state-of-the-art technologies of nano-assembly synthesis and summarize 
      the recent advances in remotely controlled nano-assembly-based DDSs activated by 
      different exogenous stimuli or endogenous/exogenous dual-stimuli. Furthermore, 
      the pioneering progress in bio-cleanable stimuli-responsive nano-assemblies that 
      holds great relevance to clinical translation will be described. Finally, we will 
      conclude with our perspectives on current issues and future development of this 
      field. The objective of this review is to outline current advances of 
      nano-assemblies as remotely controlled DDSs, in hopes of accelerating the future 
      development of intelligent nanomedicines.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Li, Fangyuan
AU  - Li F
AD  - Institute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang 
      University, Hangzhou 310058, China; Hangzhou Institute of Innovative Medicine, 
      College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
FAU - Qin, Yu
AU  - Qin Y
AD  - ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, 
      Australian Institute for Bioengineering and Nanotechnology, The University of 
      Queensland, Brisbane, Queensland 4072, Australia.
FAU - Lee, Jiyoung
AU  - Lee J
AD  - Institute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang 
      University, Hangzhou 310058, China.
FAU - Liao, Hongwei
AU  - Liao H
AD  - Institute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang 
      University, Hangzhou 310058, China.
FAU - Wang, Nan
AU  - Wang N
AD  - Institute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang 
      University, Hangzhou 310058, China.
FAU - Davis, Thomas P
AU  - Davis TP
AD  - ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, 
      Australian Institute for Bioengineering and Nanotechnology, The University of 
      Queensland, Brisbane, Queensland 4072, Australia; ARC Centre of Excellence in 
      Convergent Bio-Nano Science and Technology, Monash Institute of Pharmaceutical 
      Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, 
      Australia.
FAU - Qiao, Ruirui
AU  - Qiao R
AD  - ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, 
      Australian Institute for Bioengineering and Nanotechnology, The University of 
      Queensland, Brisbane, Queensland 4072, Australia; ARC Centre of Excellence in 
      Convergent Bio-Nano Science and Technology, Monash Institute of Pharmaceutical 
      Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, 
      Australia. Electronic address: r.qiao@uq.edu.au.
FAU - Ling, Daishun
AU  - Ling D
AD  - Institute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang 
      University, Hangzhou 310058, China; Hangzhou Institute of Innovative Medicine, 
      College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China; 
      Key Laboratory of Biomedical Engineering of the Ministry of Education, College of 
      Biomedical Engineering & Instrument Science, Zhejiang University, Hangzhou 
      310058, China. Electronic address: lingds@zju.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200408
PL  - Netherlands
TA  - J Control Release
JT  - Journal of controlled release : official journal of the Controlled Release 
      Society
JID - 8607908
RN  - 0 (Pharmaceutical Preparations)
SB  - IM
MH  - Drug Delivery Systems
MH  - Humans
MH  - *Nanoparticles
MH  - *Neoplasms/drug therapy
MH  - *Pharmaceutical Preparations
MH  - Reproducibility of Results
OTO - NOTNLM
OT  - Bio-cleanable nano-systems
OT  - Controlled drug delivery
OT  - Nano-assemblies
OT  - Stimuli-responsiveness
COIS- Declaration of Competing Interest The authors declare no conflict of interest.
EDAT- 2020/04/11 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/04/11 06:00
PHST- 2019/12/20 00:00 [received]
PHST- 2020/03/19 00:00 [revised]
PHST- 2020/03/31 00:00 [accepted]
PHST- 2020/04/11 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/04/11 06:00 [entrez]
AID - S0168-3659(20)30209-1 [pii]
AID - 10.1016/j.jconrel.2020.03.051 [doi]
PST - ppublish
SO  - J Control Release. 2020 Jun 10;322:566-592. doi: 10.1016/j.jconrel.2020.03.051. 
      Epub 2020 Apr 8.